Abigail Klein Leichman via Israel21c – The immune system can find bacteria residing within cancer cells and harness them to provoke an immune reaction against the tumor, according to a study published in Nature.
An international research team, led by researchers from the Weizmann Institute of Science in Israel, says this discovery may explain why the gut microbiome is known to affect the success of immunotherapy treatments for cancer.
Immunotherapy has dramatically improved recovery rates from certain cancers, particularly malignant melanoma, but still work in only about 40 percent of the cases.
Lead authors Shelly Kalaora and Adi Nagler analyzed tissue samples from 17 metastatic melanoma tumors derived from nine patients. They obtained bacterial genomic profiles of these tumors and then identified nearly 300 tumor peptides that can be recognized by the immune system.
Future studies may establish which bacterial peptides enhance the immune response, enabling physicians to predict the success of immunotherapy and to tailor a personalized treatment accordingly.
“Many of these peptides were shared by different metastases from the same patient or by tumors from different patients, which suggests that they have a therapeutic potential and a potent ability to produce immune activation,” Nagler said.
“Our findings suggest that bacterial peptides presented on tumor cells can serve as potential targets for immunotherapy,” Samuels said. “They may be exploited to help immune T cells recognize the tumor with greater precision, so that these cells can mount a better attack against the cancer. This approach can in the future be used in combination with existing immunotherapy drugs.”
The study’s collaborators were from the Technion – Israel Institute of Technology; Hadassah Hebrew University Medical Center; Tel Aviv University; Open University of Israel; University of Texas MD Anderson Cancer Center; Texas A&M University; Sanford Burnham Prebys Medical Discovery Institute in California; the US National Cancer Institute; Wellcome Sanger Institute, Cambridge, UK; and The Netherlands Cancer Institute.